Entweder 10000% oder Totalverlust
Optionen
| Boardmail an "Realer" |
Wertpapier: CALYPTE BIOMED. DL-.0 |
Ich werde mir die Kurse jetzt die nächsten 3 MOnate nimmer anschauen :-)
Optionen
| Boardmail an "Realer" |
Wertpapier: CALYPTE BIOMED. DL-.0 |
hat ihr einer nach dir gefragt, bei dir ist es doch nur so, alles was du anlangst
wird zu gold, *ggg
wir wissen alle selbst das diese aktie eine hopp oder top-aktie ist !!!
vielleicht spielen die Caly-Vorstände auf zeit, ich frag mich nur warum,
ist da noch was in der hinterhand, ach ja, der pinkeltest, übrigens eine geniale
idee, und kann leben retten !!!
und du regst dich auf weil wir nicht auf dich hören, mein lieber scholli,
wünsch dir ein schönes WE
und heute starten wir mit 0,03 $ in den Staaten Umsatz schätz ich auf über 20 Mill.
was mich je länger desto mehr nervt ist die informations-politik von denen & all diese insider-trades!!!
von dem Laden gibt.
Das ist doch schon mal was.
Die MK ist mir für einen Zock immer noch zu hoch.
Danke für eine der wenigen verwertbaren Infos in diesem Thread.
Schönes WE !
schau mal unter cbs.marketwatch.com bei caly,
es sind nur 195 millionen aktien im umlauf, wer hat da jetzt recht !!!
bist aber auch zur caly-fete eingeladen, als alter caly-freund !!!
nun denn schönes WE und viel Glück mit dugessa und millenium,
ich weiß genauso wenig wie du, nämlich nichts, hihi
The resale by Townsbury, Bristol and the investors providing Other Recent Financings of the common stock that they purchase from us has increased and will continue to increase the number of our publicly traded shares, which could put downward pressure on the market price of our common stock. As of December 31, 2002, of the 152 million shares outstanding, approximately one-third have been issued pursuant to these recent financings
Additionally, the holders of the original face value of $3,125,000 of the 8% Convertible Notes have the right to demand immediate repayment of the outstanding principal balance plus accrued interest due to the non-registration of the underlying shares. Although none of the holders has demanded repayment, we may be required to repay the outstanding balance of $2,985,000 prior to maturity. Accordingly, we have classified these notes as a current liability in the accompanying consolidated financial statements. The convertible note transactions generally require liquidated damages at the rate of 2% of the original principal balance for each month’s delay. The PIPE financing at $0.05 per share requires liquidated damages at the rate of 250,000 shares of Calypte common stock for each 10 days of delay. In most instances, the investor has the option of receiving liquidated damages in either cash or the Company’s common stock, although the PIPE financing agreement specifies damages to be paid in stock. Liquidated damages attributable to registration delays on the convertible notes and debentures continue to accrue at a rate of approximately $63,000 per month plus 750,000 shares attributable to the PIPE transaction.
http://knobias.10kwizard.com/...2074592&doc=1&num=58&total=150&back=1
werweiss, denk daran die paparazzis & möchtegern geilen geiern immer umher, lol
MfG
masteruz
Ja, denn wie schon desöfteren befürchtet kommt es jetzt endgültig zum Reversesplit (1:30).
ALAMEDA, Calif.--(BUSINESS WIRE)--April 4, 2003--Calypte Biomedical Corporation (OTCBB:CALY) today announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission seeking stockholder approval to amend the Company`s Amended and Restated Certificate of Incorporation to implement a reverse split of the outstanding shares of Common Stock at the ratio of 1:30 to be effected immediately upon approval of the Company`s stockholders.
The Company said that the proposed reverse split, which has received the unanimous written consent of all Directors, is being implemented to enhance the Company`s long-term financing options. If approved, the proposed reverse stock split would reduce the presently issued and outstanding shares of Common Stock to approximately 8 million from approximately 236 million as of March 31, 2003.
Other proposals requiring stockholder approval include the election of eight directors to the Company`s Board, a proposed amendment to the 2000 Equity Incentive Plan, a proposed amendment to the 1995 Director Option Plan, a proposed amendment to the 1995 Employee Stock Purchase Plan and ratification of the appointment of KPMG LLP as independent auditors.
Stockholders of record on April 4, 2003 will be eligible to vote at the annual meeting, which is scheduled for 10:00 a.m. (Pacific), Tuesday, May 20, 2003 at the Company`s headquarters offices.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC", including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
MfG
masteruz
OTC Journal:
As we stated in our review newsletter last weekend, we are not optimistic about the future of the Calypte`s stock price, which is a different issue from the future of the company. Management continues issuing enormous numbers of free trading shares below the prevailing market. Recently, the company issued another 44 million options, exercisable at $.025, and convertible into free trading shares. The suggests the shares will now trade down to $.025 to find support.
Unless the company manages to consummate a relationship with a major pharmaceutical company, we believe the stock price will continue grinding lower under the severe pressure of excess supply.
Calypte announced they will be seeking shareholder approval for a 1:30 reverse stock split, which must be viewed as a negative for share value in the short run. This was announced after the market closed on Friday.
Post reverse split, the company`s market value will be less than $10 million. We believe the technology alone is worth considerably more.
If they can raise capital with some entity who is interested in owning a piece of the technology, instead of stock they can immediately sell into the market at a discount, this one would have a chance to be a superstar.
Ich habe keine Idee,wie das mit Caly am Montag weitergeht.Gut das Splitting ist fast perfekt(kommt bloß auf die Aktionäre an) und was kommt danach?? Hat einer von euch ne Idee?Ich habe son splitting noch nicht in dem Maße mitgemacht.
mfg AIDA
Versteh ganix mehr!
Optionen
| Boardmail an "Realer" |
Wertpapier: CALYPTE BIOMED. DL-.0 |
Muss ich meinen Bestand jetzt durch 30 teilen oder wie :-)
Optionen
| Boardmail an "Realer" |
Wertpapier: CALYPTE BIOMED. DL-.0 |
aber dafür hast du z.B. statt 30000 Stück nur noch 1000 Stück,
aber erst ab 20.5.2003, also leute durchhalten, bei caly kann
bis dahin noch sehr viel passieren, *ggggggggg